Table 4.
Treatments | Survival fraction (log CFU/mL) | ||||
---|---|---|---|---|---|
Storage time (days) | |||||
0 | 3 | 7 | 14 | 21 | |
Untreated | 5.38 ± 0.30Aa | 5.00 ± 0.10Aa | 4.48 ± 0.10Ba | 3.65 ± 0.30Ca | — |
V1 | 4.89 ± 0.19Aa | 2.40 ± 0.05Bb | <2Cb | <2Cc | <2Ca |
V2 | 3.10 ± 0.05Ab | <2Bc | <2Bb | <2Bc | <2Ba |
G1 | 3.20 ± 0.10Ab | <2Bc | <2Bb | <2Bc | <2Ba |
G2 | 3.00 ± 0.10Ab | <2Bc | <2Bb | <2Bc | <2Ba |
PE1 | 5.28 ± 0.10Aa | 5.00 ± 0.13Aa | 4.49 ± 0.03Ba | 3.50 ± 0.20Ca | — |
PE2 | 5.08 ± 0.10Aa | 5.00 ± 0.04Aa | 4.66 ± 0.24Ba | 2.80 ± 0.20Cb | — |
Data is shown as means ± standard errors. Values with different lower case letters in the same column indicate significant differences (p < 0.05) between treatments. Values with different capital letters in the same row indicate significant differences (p < 0.05) with respect to storage time. V1: 2.5 mg/mL of vanillin; V2: 5 mg/mL of vanillin; G1: 0.6 μL/mL of geraniol; G2: 1.2 μL/mL of geraniol; PE1: 180 μg/mL of pomegranate extract; PE2: 360 μg/mL of pomegranate extract